Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 104 results found since Jan 2013.

Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang, Dong Zhou, Yin Dai, Yanqi Li, Jiang Wu, Quanxing Liu, Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research

Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
Abstract Although cancer vaccine-based immunotherapy holds great potential for cancer treatment, tumor-induced dendritic cell (DC) dysfunction remains to be the major obstacle for developing effective vaccines. Compared with normal DCs, tumor-associated DCs (TADCs) are less matured with poor responsiveness to Toll-like receptor (TLR) stimulation, which has been related with STAT3 hyperactivity. In the present study, Poly I:C (PIC, a TLR3 agonist), STAT3 siRNA and OVA antigen were co-encapsulated by poly (ethylene glycol)-b-poly (l-lysine)-b-poly (l-leucine) (PEG-PLL-PLLeu) polypeptide micelles to generate PMP/OVA/...
Source: Biomaterials - December 6, 2014 Category: Materials Science Authors: Luo Z, Wang C, Yi H, Li P, Pan H, Liu L, Cai L, Ma Y Tags: Biomaterials Source Type: research

The siRNA cocktail targeting IL-10 receptor and TGF-β receptor on dendritic cells potentiates tumor antigen-specific CD8(+) T cell immunity.
This article is protected by copyright. All rights reserved. PMID: 25753156 [PubMed - as supplied by publisher]
Source: Clinical and Developmental Immunology - March 8, 2015 Category: Allergy & Immunology Authors: Ahn YH, Hong SO, Kim JH, Noh KH, Song KH, Lee YH, Jeon JH, Kim DW, Seo JH, Kim TW Tags: Clin Exp Immunol Source Type: research

The siRNA cocktail targeting IL‐10 receptor and TGF‐β receptor on dendritic cells potentiates tumor antigen‐specific CD8+ T cell immunity
This article is protected by copyright. All rights reserved.
Source: Clinical and Experimental Immunology - March 8, 2015 Category: Allergy & Immunology Authors: Ye‐Hyeon Ahn, Soon‐Oh Hong, Jin Hee Kim, Kyung Hee Noh, Kwon‐Ho Song, Young‐Ho Lee, Ju‐Hong Jeon, Dong‐Wan Kim, Jae Hong Seo, Tae Woo Kim Tags: Original Article Source Type: research

The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor‐β receptor on dendritic cells potentiates tumour antigen‐specific CD8+ T cell immunity
In this study, we used small interfering RNA (siRNA) to silence the expression of endogenous molecules in DCs, which can sense immunosuppressive factors. Among the siRNAs targeting various immunosuppressive molecules, we observed that DCs transfected with siRNA targeting IL‐10 receptor alpha (siIL‐10RA) initiated the strongest antigen‐specific CD8+ T cell immune responses. The potency of siIL‐10RA was enhanced further by combining it with siRNA targeting TGF‐β receptor (siTGF‐βR), which was the next best option during the screening of this study, or the previously selected immunoadjuvant siRNA targeting phosp...
Source: Clinical and Experimental Immunology - May 17, 2015 Category: Allergy & Immunology Authors: Y.‐H. Ahn, S.‐O. Hong, J. H. Kim, K. H. Noh, K.‐H. Song, Y.‐H. Lee, J.‐H. Jeon, D.‐W. Kim, J. H. Seo, T. W. Kim Tags: Original Article Source Type: research

A Novel and Efficient Technology for Targeted Delivery of siRNA
The biological phenomenon of RNA interference (RNAi) has much promise for developing therapeutics to a variety of diseases. However, development of RNAi therapies remains mainly in preclinical stages largely because of difficulties in delivering small inhibitory RNAs (siRNA) and short hairpin RNAs (shRNA) into target cells. Although viral vector-based siRNA delivery systems have been widely used, their specificity and safety remains significant issue. Without a solution to this delivery problem, RNAi cannot fulfill its therapeutic promise. Investigators at the National Institutes of Health have developed novel compositions...
Source: NIH OTT Licensing Opportunities - January 1, 2009 Category: Research Authors: admin Source Type: research

The MRI-Visible Nanocomposite Facilitates the Delivery and Tracking of siRNA Loaded DC Vaccine in the Breast Cancer Model
Dendritic cell (DC) vaccines have recently been developed for the treatment of various cancers but often do not function as well as expected, primarily due to the highly complex in vivo immune environment. This proof-of-principle study aimed to test the feasibility of modulating the in vivo behaviors of DC vaccines (DCVs) by introducing siRNA-laden magnetic resonance (MR) imaging nanovectors into cells, while providing visible information on their homing to lymph nodes. The N-alkyl-PEI2k-LAC/SPIO nanocomposites were prepared and characterized, showing favorable properties of siRNA transfection and MRI labeling efficiency i...
Source: Frontiers in Oncology - February 5, 2021 Category: Cancer & Oncology Source Type: research

The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.
Abstract Success of an immunotherapy for cancer often depends on the critical balance of T helper 1 (Th1) and T helper 2 (Th2) responses driven by antigen presenting cells, specifically dendritic cells (DCs). Th1-driven cytotoxic T cell (CTL) responses are key to eliminating tumor cells. It is well established that CpG oligonucleotides (ODN), a widely studied Toll-like receptor 9 (TLR9) agonist, used to enhance Th1 response, also induces high levels of the anti-inflammatory, Th2-promoting cytokine IL10, which could dampen the resulting Th1 response. Biomaterials-based immunomodulatory strategies that can reduce IL...
Source: Biomaterials - April 7, 2014 Category: Materials Science Authors: Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, Roy K Tags: Biomaterials Source Type: research

siRNA nanotherapeutics: a promising strategy for anti-HBV therapy
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and liver cirrhosis worldwide. In spite of the numerous advances in the treatment of CHB, drugs and vaccines have failed because of many factors like complexity, resistance, toxicity, and heavy cost. New RNA interference (RNAi)-based technologies have developed innovative strategies to target Achilles' heel of the several hazardous diseases involving cancer, some genetic disease, autoimmune illnesses, and viral disorders particularly hepatitis B virus (HBV) infections. Naked siRNA delivery has serious challenges including failure to cross ...
Source: IET Nanobiotechnology - June 21, 2019 Category: Nanotechnology Source Type: research

Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
CONCLUSIONS: These findings suggest that the use of new nanocarriers such as SPION-C-CMD-FA could be an effective way to use as a novel combination therapy consisting of β-catenin siRNA, IL-15, and DC vaccine to treat cancer.PMID:35166995 | DOI:10.1007/s11095-022-03169-2
Source: Cell Research - February 15, 2022 Category: Cytology Authors: Armin Mahmoud Salehi Kheshti Farnaz Hajizadeh Asal Barshidi Bentolhoda Rashidi Farbod Ebrahimi Simin Bahmanpour Vahid Karpisheh Fatemeh Karimian Noukabadi Fariba Karoon Kiani Hadi Hassannia Fatemeh Atyabi Seyed Hossein Kiaie Fatah Kashanchi Jamshid Gholiz Source Type: research

Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy
This technology comprises live, attenuated Salmonella strains as a delivery system for small interfering double-stranded RNA (siRNA)-based tumor therapy. The inventors' data provide the first convincing evidence that Salmonella can be used for delivering plasmid-based siRNAs into tumors growing in vivo. Claimed in the related patent application are methods of inhibiting the growth or reducing the volume of solid cancer tumors using the si-RNA constructs directed against genes that promote tumor survival and cancer cell growth. The Stat3-siRNAs carried by an attenuated S. typhimurium described in the application exhibit tum...
Source: NIH OTT Licensing Opportunities - January 9, 2009 Category: Research Authors: admin Source Type: research